Research programme: phosphodiesterase 10 inhibitors - Merck
Alternative Names: SCH 1518291Latest Information Update: 16 Jul 2016
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Pyridones; Pyrimidines; Small molecules
- Mechanism of Action Phosphodiesterase 10A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA (PO)
- 01 Sep 2011 Pharmacodynamics data from a preclinical trial in Schizophrenia presented at the 242nd American Chemical Society National Meeting (242nd-ACS-2011)
- 29 Oct 2009 Preclinical trials in Schizophrenia in USA (unspecified route)